OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary…

By C. Aghajanian, S. Blank, B. Goff, P. Judson, M. Teneriello, A. Husain, M. Sovak, J. Yi, L. R. Nycum. Journal of Clinical Oncology, 2011

1,277 citations recorded by the source corpus.

Subfields: Oncology, Reproductive Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/1ea78b4c4902251e2ce78fbb649dc04e7c15c93a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. A. Adamis
2. N. Ferrara
3. Daniel Chen
4. R. Apte

In Reproductive Medicine

1. Jonathan A. Ledermann
2. C. Sessa
3. D. Querleu
4. M. Mirza

Citations in the corpus

• ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease (2019, methodology): “Bevacizumab with platinum combinations (either paclitaxel or gemcitabine followed by bevacizumab maintenance) has demonstrated a significant benefit in PFS [25, 266, 278, 279].”
• Ten years of anti-vascular endothelial growth factor therapy (2016, background): “OS was not increased, but similar to other trials 92 , patient crossover to subsequent therapies (bevacizumab or other agents) complicates the assessment of the survival effects of bevacizumab 91 .”
• ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. (2019, background): “OS was similar in both groups, which might partially be explained by the use of bevacizumab as a subsequent anticancer therapy in 43.9% of patients who were allocated to placebo in the study.278 The administration of bevacizumab in combination with paclitaxel/carboplatin in the GOG 213 study279 show”
• A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “61) 3 [118]”
• Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. (2014, positive): “Bevacizumab combined with chemotherapy and continued as a single agent significantly improved PFS compared with chemotherapy alone in the first-line setting (GOG-0218 [Gynecologic Oncology Group] and ICON7 [International Collaboration on Ovarian Neoplasms])(16,17) and the platinum-sensitive recurren”